Activity of pembrolizumab in BCG-refractory papillary bladder cancer

Published Date: 02 Mar 2023

Pembrolizumab monotherapy has been shown to be effective against cancer in patients with unresectable high-risk bladder cancer who have not responded to standard BCG therapy.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Potential targets for treating the most common type of liver cancer in children have been identified by a collaborative study.

2.

Study identifies new approach to protect the brain during radiation therapy

3.

While most cancer screenings won't prolong lives, there are still good reasons to continue screening.

4.

Chemo-Free Quadruplet Shows Promise as DLBCL's First Therapy.

5.

Radiation therapy for patients with breast cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot